AUG 19, 2020 3:08 PM PDT

Cancer Mutation Improves Chemo Drug Performance

WRITTEN BY: Tara Fernandez

 

When it comes to cancer biomarkers, it’s often the genetic signatures that are associated with poor patient outcomes that take center stage. Take for example triple-negative breast cancer, a diagnostic marker for a condition that is notoriously difficult to treat and puts patients at significantly higher risks of relapse after therapy.

A team of cancer researchers based at the Terry Fox Research Institute have identified a gene mutation in lymphoma that serves as a biomarker for the opposite — it’s associated with improved patient survival instead.

Scientists David Scott and Christian Steidl led the study which was published in Nature Medicine. Here, they describe that patients with Diffuse Large B-cell Lymphoma, or DLBCL that lack a particular protein called TMEM30A are actually more susceptible to chemotherapeutic drugs, leading to better outcomes.

Shannon Healy, the first author of the paper said, “In contrast to most studies that describe gene mutations associated with poor survival, we observed that DLBCL cells with complete loss of TMEM30A actually showed increased uptake of cytotoxic drugs, most notably those that are used to treat DLBCL, such as doxorubicin and vincristine.”

DLBCL is the most common type of non-Hodgkin lymphoma worldwide. In the United States, almost 20,000 people are diagnosed with this aggressive cancer annually. It affects a particular subset of immune cells called B-lymphocytes which produce antibodies to resist infections.

The team’s discovery sheds light on why some cancer patients respond much more favorably to cytotoxic drugs than others. In the case of DLBCL, the research team believes that the TMEM30A mutation allows these cancer-killing drugs to pass through the cell membrane more efficiently. This could translate to a new generation of future therapeutics that target TMEM30A to shuttle the cytotoxic molecules into cancer cells.

 


Sources: Nature Medicine, The Terry Fox Research Institute.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 08, 2020
Health & Medicine
The Myths About CBD and Coronavirus
JUL 08, 2020
The Myths About CBD and Coronavirus
Research collected over the last 20 years suggests that cannabidiol – the primary cannabinoid in CBD oil – h ...
JUL 08, 2020
Immunology
Scientists Use Genetics to Control Regulatory T Cells
JUL 08, 2020
Scientists Use Genetics to Control Regulatory T Cells
The ability to control regulatory T cells of the immune system has long been sought out by scientists, especially those ...
JUL 13, 2020
Drug Discovery & Development
Russia Completes First Human Trial for COVID-19 Vaccine
JUL 13, 2020
Russia Completes First Human Trial for COVID-19 Vaccine
The Sechenov University Center for Clinical Research in Moscow, Russia, has completed its first round of clinical trials ...
AUG 19, 2020
Cell & Molecular Biology
Mild COVID-19 Cases Induce an Immune Cell Response
AUG 19, 2020
Mild COVID-19 Cases Induce an Immune Cell Response
As the pandemic virus, SARS-CoV-2 continues to cause tens of thousands of new cases of COVID-19 every day in the United ...
OCT 01, 2020
Immunology
Immune Cells and MS: The Good, the Bad, and the Maybe
OCT 01, 2020
Immune Cells and MS: The Good, the Bad, and the Maybe
Much like electrical wires that are encased in plastic insulating sheaths, nerve cells also are also surrounded by a sim ...
OCT 27, 2020
Immunology
The Genetics of Skin Inflammation, Seen With Unprecedented Clarity
OCT 27, 2020
The Genetics of Skin Inflammation, Seen With Unprecedented Clarity
A recent study published in Immunity details MIT scientists’ exploration of the underlying mechanisms of inflammat ...
Loading Comments...